We focused on developing differentiated, innovative immuno-oncology medicines.
We are committed to improving patient lives by developing differentiated innovative cancer treatments that help people live better and longer.
Our vision Our vision
Adlai Nortye focuses on developing differentiated, innovative immuno-oncology medicines. We are committed to improving patient life quality, and extending their life span. We believe we can meet the needs of cancer patients for new innovative treatments through the unremitting efforts of our scientists in researching and developing our product candidates. To realize our mission ----- turn cancer into a non-fatal disease and even cure it, so that patients can live better and live longer!
Clinical Trials
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

product:AN0025(EP4 Antagonist)

Indications:Solid Tumors
ClinicalTrials.gov Identifier: NCT04432857

View More
Preoperative Radiotherapy and AN0025 in Rectum Cancer (PRAER 1)

product:AN0025(EP4 Antagonist)

Indications:Rectal Cancer
ClinicalTrials.gov Identifier: NCT03152370

View More
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)

product:AN2025(buparlisib, pan-P13K inhibiter)

Indications:HNSCC
ClinicalTrials.gov Identifier: NCT04338399

View More
A phase III study of Pelareorep Plus Paclitixel VS. Paclitaxel Alone in Advanced/Metastatic Breast Cancer ( Bridging Study)

product:AN1004 ( pelareorep)

Indications:Advanced/ Metastatic Breast Cancer
Chinadrugtrials.org.cn:CTR20201625

View More